These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 11172417)

  • 1. All angiogenesis is not the same: Distinct patterns of response to antiangiogenic therapy in experimental neuroblastoma and Wilms tumor.
    Kim E; Moore J; Huang J; Soffer S; Manley CA; O'Toole K; Middlesworth W; Stolar CJ; Kandel JJ; Yamashiro DJ
    J Pediatr Surg; 2001 Feb; 36(2):287-90. PubMed ID: 11172417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination antiangiogenic therapy: increased efficacy in a murine model of Wilms tumor.
    Soffer SZ; Moore JT; Kim E; Huang J; Yokoi A; Manley C; O'Toole K; Stolar C; Middlesworth W; Yamashiro DJ; Kandel JJ
    J Pediatr Surg; 2001 Aug; 36(8):1177-81. PubMed ID: 11479851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-VEGF antibody in experimental hepatoblastoma: suppression of tumor growth and altered angiogenesis.
    McCrudden KW; Hopkins B; Frischer J; Novikov A; Huang J; Kadenhe A; New T; Yokoi A; Yamashiro DJ; Kandel JJ; Middlesworth W
    J Pediatr Surg; 2003 Mar; 38(3):308-14; discussion 308-14. PubMed ID: 12632340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Highly specific antiangiogenic therapy is effective in suppressing growth of experimental Wilms tumors.
    Huang J; Moore J; Soffer S; Kim E; Rowe D; Manley CA; O'Toole K; Middlesworth W; Stolar C; Yamashiro D; Kandel J
    J Pediatr Surg; 2001 Feb; 36(2):357-61. PubMed ID: 11172434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of primary tumor growth in a mouse model of human neuroblastoma.
    Rowe DH; Huang J; Li J; Manley C; O'Toole KM; Stolar CJ; Yamashiro DJ; Kandel JJ
    J Pediatr Surg; 2000 Jun; 35(6):977-81. PubMed ID: 10873048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel use of an established agent: Topotecan is anti-angiogenic in experimental Wilms tumor.
    Soffer SZ; Kim E; Moore JT; Huang J; Yokoi A; Manley C; O'Toole K; Middlesworth W; Stolar C; Yamashiro D; Kandel J
    J Pediatr Surg; 2001 Dec; 36(12):1781-4. PubMed ID: 11733906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of potent VEGF blockade on experimental Wilms tumor and its persisting vasculature.
    Frischer JS; Huang J; Serur A; Kadenhe-Chiweshe A; McCrudden KW; O'Toole K; Holash J; Yancopoulos GD; Yamashiro DJ; Kandel JJ
    Int J Oncol; 2004 Sep; 25(3):549-53. PubMed ID: 15289855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wilms' tumor growth is suppressed by antiangiogenic pigment epithelium-derived factor in a xenograft model.
    Abramson LP; Stellmach V; Doll JA; Cornwell M; Arensman RM; Crawford SE
    J Pediatr Surg; 2003 Mar; 38(3):336-42; discussion 336-42. PubMed ID: 12632345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles.
    Li L; Wartchow CA; Danthi SN; Shen Z; Dechene N; Pease J; Choi HS; Doede T; Chu P; Ning S; Lee DY; Bednarski MD; Knox SJ
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1215-27. PubMed ID: 15001266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM
    Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. rAAV-mediated long-term liver-generated expression of an angiogenesis inhibitor can restrict renal tumor growth in mice.
    Davidoff AM; Nathwani AC; Spurbeck WW; Ng CY; Zhou J; Vanin EF
    Cancer Res; 2002 Jun; 62(11):3077-83. PubMed ID: 12036917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression.
    Li D; Williams JI; Pietras RJ
    Oncogene; 2002 Apr; 21(18):2805-14. PubMed ID: 11973639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.
    Viloria-Petit A; Crombet T; Jothy S; Hicklin D; Bohlen P; Schlaeppi JM; Rak J; Kerbel RS
    Cancer Res; 2001 Jul; 61(13):5090-101. PubMed ID: 11431346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.
    Sweeney P; Karashima T; Kim SJ; Kedar D; Mian B; Huang S; Baker C; Fan Z; Hicklin DJ; Pettaway CA; Dinney CP
    Clin Cancer Res; 2002 Aug; 8(8):2714-24. PubMed ID: 12171905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thalidomide is anti-angiogenic in a xenograft model of neuroblastoma.
    Kaicker S; McCrudden KW; Beck L; New T; Huang J; Frischer JS; Serur A; Kadenhe-Chiweshe A; Yokoi A; Kandel JJ; Yamashiro DJ
    Int J Oncol; 2003 Dec; 23(6):1651-5. PubMed ID: 14612937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.
    Pastorino F; Brignole C; Marimpietri D; Cilli M; Gambini C; Ribatti D; Longhi R; Allen TM; Corti A; Ponzoni M
    Cancer Res; 2003 Nov; 63(21):7400-9. PubMed ID: 14612539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longterm recombinant adeno-associated, virus-mediated, liver-generated expression of an angiogenesis inhibitor improves survival in mice with disseminated neuroblastoma.
    Streck CJ; Zhou J; Ng CY; Zhang Y; Nathwani AC; Davidoff AM
    J Am Coll Surg; 2004 Jul; 199(1):78-86. PubMed ID: 15217634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts.
    Holloway SE; Beck AW; Shivakumar L; Shih J; Fleming JB; Brekken RA
    Ann Surg Oncol; 2006 Aug; 13(8):1145-55. PubMed ID: 16791450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin.
    Lamszus K; Brockmann MA; Eckerich C; Bohlen P; May C; Mangold U; Fillbrandt R; Westphal M
    Clin Cancer Res; 2005 Jul; 11(13):4934-40. PubMed ID: 16000592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential vascular and transcriptional responses to anti-vascular endothelial growth factor antibody in orthotopic human pancreatic cancer xenografts.
    Bockhorn M; Tsuzuki Y; Xu L; Frilling A; Broelsch CE; Fukumura D
    Clin Cancer Res; 2003 Sep; 9(11):4221-6. PubMed ID: 14519649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.